Does the media favor MDXG or PRQR?

In the previous week, ProQR Therapeutics had 5 more articles in the media than MiMedx Group. MarketBeat recorded 10 mentions for ProQR Therapeutics and 5 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.46 beat ProQR Therapeutics' score of -0.36 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer PRQR or IRWD?

In the previous week, ProQR Therapeutics had 8 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 10 mentions for ProQR Therapeutics and 2 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.42 beat ProQR Therapeutics' score of -0.36 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PRQR or NVCT?

In the previous week, ProQR Therapeutics had 8 more articles in the media than Nuvectis Pharma. MarketBeat recorded 10 mentions for ProQR Therapeutics and 2 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.00 beat ProQR Therapeutics' score of -0.36 indicating that Nuvectis Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SLN or PRQR?

In the previous week, ProQR Therapeutics had 7 more articles in the media than Silence Therapeutics. MarketBeat recorded 10 mentions for ProQR Therapeutics and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 beat ProQR Therapeutics' score of -0.36 indicating that Silence Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CLYM or PRQR?

In the previous week, ProQR Therapeutics had 4 more articles in the media than Climb Bio. MarketBeat recorded 10 mentions for ProQR Therapeutics and 6 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.47 beat ProQR Therapeutics' score of -0.36 indicating that Climb Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

ProQR Therapeutics (PRQR) Competitors

$1.57 -0.06 (-3.68%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$1.59 +0.02 (+1.21%)

As of 07:56 AM Eastern

Compare

PRQR vs. MDXG, IRWD, NVCT, SLN, and CLYM

Should you buy ProQR Therapeutics stock or one of its competitors? ProQR Therapeutics's main competitors and comparable companies include MiMedx Group (MDXG), Ironwood Pharmaceuticals (IRWD), Nuvectis Pharma (NVCT), Silence Therapeutics (SLN), and Climb Bio (CLYM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ProQR Therapeutics compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

MiMedx Group has a net margin of 1.76% compared to ProQR Therapeutics' net margin of -223.51%. MiMedx Group's return on equity of 12.09% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
ProQR Therapeutics	-223.51%	-73.83%	-35.14%

MiMedx Group has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.61	$48.58M	$0.04	115.50
ProQR Therapeutics	$17.99M	9.19	-$47.73M	-$0.46	N/A

MiMedx Group presently has a consensus target price of $8.57, indicating a potential upside of 85.53%. ProQR Therapeutics has a consensus target price of $7.60, indicating a potential upside of 384.08%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, ProQR Therapeutics had 5 more articles in the media than MiMedx Group. MarketBeat recorded 10 mentions for ProQR Therapeutics and 5 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 0.46 beat ProQR Therapeutics' score of -0.36 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

MiMedx Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

MiMedx Group beats ProQR Therapeutics on 11 of the 15 factors compared between the two stocks.

How does ProQR Therapeutics compare to Ironwood Pharmaceuticals?

ProQR Therapeutics (NASDAQ:PRQR) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

ProQR Therapeutics currently has a consensus target price of $7.60, suggesting a potential upside of 384.08%. Ironwood Pharmaceuticals has a consensus target price of $6.23, suggesting a potential upside of 61.07%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

ProQR Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 8 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 10 mentions for ProQR Therapeutics and 2 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.42 beat ProQR Therapeutics' score of -0.36 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ironwood Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ironwood Pharmaceuticals has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	9.19	-$47.73M	-$0.46	N/A
Ironwood Pharmaceuticals	$296.15M	2.16	$24.02M	$0.77	5.03

32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to ProQR Therapeutics' net margin of -223.51%. Ironwood Pharmaceuticals' return on equity of -58.38% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

Summary

Ironwood Pharmaceuticals beats ProQR Therapeutics on 11 of the 17 factors compared between the two stocks.

How does ProQR Therapeutics compare to Nuvectis Pharma?

ProQR Therapeutics (NASDAQ:PRQR) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

In the previous week, ProQR Therapeutics had 8 more articles in the media than Nuvectis Pharma. MarketBeat recorded 10 mentions for ProQR Therapeutics and 2 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 0.00 beat ProQR Therapeutics' score of -0.36 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Nuvectis Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nuvectis Pharma has lower revenue, but higher earnings than ProQR Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	9.19	-$47.73M	-$0.46	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

ProQR Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market.

ProQR Therapeutics currently has a consensus target price of $7.60, suggesting a potential upside of 384.08%. Nuvectis Pharma has a consensus target price of $36.25, suggesting a potential upside of 80.08%. Given ProQR Therapeutics' higher possible upside, equities research analysts plainly believe ProQR Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Nuvectis Pharma has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. ProQR Therapeutics' return on equity of -73.83% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Nuvectis Pharma	N/A	-184.25%	-105.24%

Summary

ProQR Therapeutics beats Nuvectis Pharma on 9 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk.

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ProQR Therapeutics has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,023.57	-$88.61M	-$1.28	N/A
ProQR Therapeutics	$17.99M	9.19	-$47.73M	-$0.46	N/A

Silence Therapeutics currently has a consensus price target of $53.50, suggesting a potential upside of 461.97%. ProQR Therapeutics has a consensus price target of $7.60, suggesting a potential upside of 384.08%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

ProQR Therapeutics has a net margin of -223.51% compared to Silence Therapeutics' net margin of -8,943.86%. ProQR Therapeutics' return on equity of -73.83% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
ProQR Therapeutics	-223.51%	-73.83%	-35.14%

Silence Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 7 more articles in the media than Silence Therapeutics. MarketBeat recorded 10 mentions for ProQR Therapeutics and 3 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.00 beat ProQR Therapeutics' score of -0.36 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

ProQR Therapeutics beats Silence Therapeutics on 10 of the 17 factors compared between the two stocks.

How does ProQR Therapeutics compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

In the previous week, ProQR Therapeutics had 4 more articles in the media than Climb Bio. MarketBeat recorded 10 mentions for ProQR Therapeutics and 6 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.47 beat ProQR Therapeutics' score of -0.36 indicating that Climb Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

69.8% of Climb Bio shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 2.6% of Climb Bio shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ProQR Therapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A
ProQR Therapeutics	$17.99M	9.19	-$47.73M	-$0.46	N/A

Climb Bio has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Climb Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. Climb Bio's return on equity of -31.79% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.79%	-30.79%
ProQR Therapeutics	-223.51%	-73.83%	-35.14%

Climb Bio currently has a consensus price target of $27.62, suggesting a potential upside of 154.29%. ProQR Therapeutics has a consensus price target of $7.60, suggesting a potential upside of 384.08%. Given ProQR Therapeutics' higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Climb Bio and ProQR Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRQR vs. The Competition

Export

Metric	ProQR Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$171.74M	$3.87B	$7.19B	$13.37B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-3.41	13.89	274.66	26.04
Price / Sales	9.01	1,168.75	568.58	76.65
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	2.96	16.28	10.88	6.27
Net Income	-$47.73M	-$22.69M	$3.50B	$382.01M
7 Day Performance	-3.98%	-2.87%	-1.84%	-1.60%
1 Month Performance	-21.11%	-11.16%	-6.36%	-4.63%
1 Year Performance	-37.20%	8.31%	3.07%	-0.95%

ProQR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
PRQR ProQR Therapeutics	3.7023 of 5 stars	$1.57 -3.7%	$7.60 +384.1%	-33.5%	$171.74M	$18.36M	N/A	166
MDXG MiMedx Group	2.358 of 5 stars	$4.67 -0.2%	$8.57 +83.5%	-34.9%	$682.16M	$418.63M	116.78	808
IRWD Ironwood Pharmaceuticals	2.3361 of 5 stars	$4.16 +1.0%	$6.23 +49.8%	+144.9%	$680.79M	$296.15M	5.40	100
NVCT Nuvectis Pharma	1.8155 of 5 stars	$20.53 -1.3%	$36.25 +76.6%	+223.1%	$679.32M	N/A	N/A	13
SLN Silence Therapeutics	2.5344 of 5 stars	$10.80 -3.6%	$53.50 +395.4%	+81.3%	$674.34M	$560K	N/A	88

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRQR) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProQR Therapeutics (PRQR) Competitors

PRQR vs. MDXG, IRWD, NVCT, SLN, and CLYM

How does ProQR Therapeutics compare to MiMedx Group?

Summary

How does ProQR Therapeutics compare to Ironwood Pharmaceuticals?

Summary

How does ProQR Therapeutics compare to Nuvectis Pharma?

Summary

How does ProQR Therapeutics compare to Silence Therapeutics?

Summary

How does ProQR Therapeutics compare to Climb Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProQR Therapeutics (PRQR) Competitors

PRQR vs. MDXG, IRWD, NVCT, SLN, and CLYM

How does ProQR Therapeutics compare to MiMedx Group?

Is MDXG or PRQR more profitable?

Which has better valuation and earnings, MDXG or PRQR?

Do analysts prefer MDXG or PRQR?

Does the media favor MDXG or PRQR?

Which has more volatility and risk, MDXG or PRQR?

Do institutionals and insiders believe in MDXG or PRQR?

Summary

How does ProQR Therapeutics compare to Ironwood Pharmaceuticals?

Do analysts rate PRQR or IRWD?

Which has more volatility & risk, PRQR or IRWD?

Does the media prefer PRQR or IRWD?

Which has better earnings and valuation, PRQR or IRWD?

Do insiders & institutionals have more ownership in PRQR or IRWD?

Is PRQR or IRWD more profitable?

Summary

How does ProQR Therapeutics compare to Nuvectis Pharma?

Does the media refer more to PRQR or NVCT?

Do insiders and institutionals hold more shares of PRQR or NVCT?

Which has higher earnings & valuation, PRQR or NVCT?

Which has more risk and volatility, PRQR or NVCT?

Do analysts recommend PRQR or NVCT?

Is PRQR or NVCT more profitable?

Summary

How does ProQR Therapeutics compare to Silence Therapeutics?

Do institutionals and insiders have more ownership in SLN or PRQR?

Which has stronger earnings and valuation, SLN or PRQR?

Do analysts rate SLN or PRQR?

Is SLN or PRQR more profitable?

Which has more risk and volatility, SLN or PRQR?

Does the media prefer SLN or PRQR?

Summary

How does ProQR Therapeutics compare to Climb Bio?

Does the media prefer CLYM or PRQR?

Do institutionals & insiders hold more shares of CLYM or PRQR?

Which has better valuation and earnings, CLYM or PRQR?

Which has more risk and volatility, CLYM or PRQR?

Is CLYM or PRQR more profitable?

Do analysts prefer CLYM or PRQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools